How Biotech Startups Use Adaptive Trial Designs

Episode 32 of Biotech Business with Fexingo dives into adaptive clinical trial designs — a statistical approach that lets biotech startups modify trial parameters mid-study based on interim data. Lucas and Luna explore how this flexibility saves time and money, using the example of a mid-stage oncology trial that cut enrollment by 40% without sacrificing statistical power. They discuss Bayesian vs. frequentist methods, the FDA's adaptive design guidance (updated in 2023), and why small biotechs are leading adoption over Big Pharma. Specific numbers: how an adaptive Phase 2 trial can reduce sample size by 30–50% and shorten development timelines by 12–18 months. The episode also covers risks like operational bias and regulatory scrutiny. A concrete case: how a startup using adaptive basket trials tested three drugs simultaneously in biomarker-defined subgroups. Perfect for founders, investors, and anyone curious about smarter clinical development. #AdaptiveTrialDesign #ClinicalTrials #BiotechStartup #FDA #BayesianStatistics #DrugDevelopment #OncologyTrials #BasketTrial #PlatformTrial #Phase2 #Biostatistics #RareDisease #PrecisionMedicine #Business #Technology #FexingoBusiness #BusinessPodcast #LifeSciences Keep every episode free: buymeacoffee.com/fexingo